This company has become the most profitable pharmaceutical enterprise among the world's top 500, relying on COVID-19 Vaccine and Medicine Cominernity | Pfizer | Vaccine
In 2022, Pfizer Pharmaceutical Co., Ltd. became the world's first pharmaceutical company with annual revenue exceeding 100 billion US dollars.
In the latest Fortune Global 500 list released on August 2nd, Pfizer is also the world's most profitable pharmaceutical company, and is listed among the 50 most profitable companies in the Fortune Global 500.
According to reports, in 2022, Pfizer's operating revenue reached 100.33 billion yuan, a year-on-year increase of 23.4%; The profit was 31.372 billion yuan, a year-on-year increase of 42.7%. Both in terms of revenue and profit, Pfizer ranks first in the pharmaceutical industry among the Fortune 500 companies.
Meanwhile, Pfizer ranks 102nd in the Fortune Global 500, an increase of 35 places from the previous year.
This is mainly due to the big sales of Pfizer's COVID-19 vaccine Comirnaty and COVID-19 drug Paxlovid. COVID-19 Vaccine and COVID-19 Oral Medicine have cumulatively contributed more than half of the company's revenue, and the sales revenue will reach 56.739 billion dollars in 2022.
Among the top ten best-selling drugs in the world in 2022, Pfizer's COVID-19 Vaccine Comirnaty will become the "drug king", and its sales will reach 37.81 billion dollars in 2022.
Like Pfizer, MSD also benefited from the sales of COVID-19 Medicine.
Merck is also ranked 231st on the Fortune Global 500, an increase of 31 places from the previous year. In 2022, Merck's operating revenue was $59.283 billion, a year-on-year increase of 15.8%; The profit was 14.519 billion US dollars, a year-on-year increase of 11.3%. In 2022, MSD COVID-19 oral medicine Lagevrio contributed 5.684 billion yuan to the company.
![This company has become the most profitable pharmaceutical enterprise among the world's top 500, relying on COVID-19 Vaccine and Medicine Cominernity | Pfizer | Vaccine](https://a5qu.com/upload/images/4e7fe33c5b455d8c280ab3583ca98821.jpg)
However, in 2023, as the COVID-19 weakens and the demand for COVID-19 vaccine and COVID-19 drugs decreases, the income of Pfizer and MSD will decline.
Recently, Pfizer and MSD both disclosed their performance in the 2023 semi annual report.
Data shows that Pfizer's total revenue in the first half of 2023 was 31 billion US dollars, a year-on-year decrease of 42%; Among them, the revenue in the second quarter was 12.7 billion US dollars, a year-on-year decrease of 54%. The overall decline of the company's performance was mainly due to the decline in patient demand for COVID-19 oral drug Paxlovid and COVID-19 vaccine Comirnaty.
Pfizer has also reconfirmed its 2023 performance guidance in this quarter's financial report, consistent with previous plans, with an expected annual revenue of $67 billion to $70 billion.
Merck's total revenue in the first half of 2023 was $29.522 billion, a year-on-year decrease of 3%; The revenue in the second quarter was 15.035 billion US dollars, a year-on-year increase of 3%. The decline in the company's revenue in the first half of the year was mainly due to the sharp decrease in the revenue of COVID-19 drug Lagevrio and the decline in sales of two hypoglycemic drugs.
Currently, Merck's revenue mainly relies on the sales of two major products, PD-1 monoclonal antibody K drug and HPV vaccine, both contributing a total of 16.495 billion US dollars in the first half of 2023.
It is worth noting that the global "medicine king" in 2023 may be replaced by Merck's K-drug. Due to the penetration of early cancer treatment and the huge clinical demand for metastatic cancer, Merck's K-drug sales continued to reach a historic high in the first half of 2023, reaching $12.065 billion, a year-on-year increase of 20%. The market believes that in the second half of the year, K-drug will receive approval decisions for new adjuvant/adjuvant treatments for NSCLC, first-line treatments for HER2 negative and HER2 positive gastric cancer, adjuvant treatments for NSCLC, as well as comprehensive approvals for Merkel cell carcinoma and second-line treatments for hepatocellular carcinoma. The drug's annual sales are expected to reach a new high, and there is no doubt that it will ascend to the throne of "drug king".